Identification
- Generic Name
- Besifovir dipivoxil
- DrugBank Accession Number
- DB05020
- Background
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Besifovir dipivoxil (DB05020)
- Weight
- Average: 527.515
Monoisotopic: 527.214500073 - Chemical Formula
- C22H34N5O8P
- Synonyms
- Not Available
- External IDs
- AN-380
- ANA380
- LB 80380
- LB-80380
- LB80380
Pharmacology
- Indication
Investigated for use/treatment in hepatitis (viral, B).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Besifovir dipivoxil is an inhibitor of the HBV polymerase. It is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Target Actions Organism UDNA polymerase Not Available HBV - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S9I9P4J8IU
- CAS number
- 441785-26-8
- InChI Key
- JLKJXDOWBVVABZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H34N5O8P/c1-20(2,3)17(28)31-12-34-36(30,35-13-32-18(29)21(4,5)6)14-33-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26)
- IUPAC Name
- {[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropoxy}methyl)({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl]oxy}methyl 2,2-dimethylpropanoate
- SMILES
- CC(C)(C)C(=O)OCOP(=O)(COC1(CN2C=NC3=CN=C(N)N=C23)CC1)OCOC(=O)C(C)(C)C
References
- General References
- Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL: A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83. [Article]
- External Links
- PubChem Substance
- 347909895
- ChemSpider
- 4981031
- ChEMBL
- CHEMBL1652128
- ZINC
- ZINC000003989271
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Food Effect / Health, Subjects 1 4 Unknown Status Treatment Viral Hepatitis B 1 2 Completed Treatment Chronic Hepatitis B Infection 1 2 Unknown Status Treatment Chronic Hepatitis B Infection 1 1 Completed Not Available Chronic Hepatitis B Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.744 mg/mL ALOGPS logP 1.39 ALOGPS logP 3.34 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 16.67 Chemaxon pKa (Strongest Basic) 3.58 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 166.98 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 126.73 m3·mol-1 Chemaxon Polarizability 53.3 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 237.3342065 predictedDarkChem Lite v0.1.0 [M+H]+ 237.0740065 predictedDarkChem Lite v0.1.0 [M+Na]+ 237.7508065 predictedDarkChem Lite v0.1.0
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- HBV
- Pharmacological action
- Unknown
- General Function
- Rna-dna hybrid ribonuclease activity
- Specific Function
- Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ri...
- Gene Name
- Not Available
- Uniprot ID
- O11885
- Uniprot Name
- Protein P
- Molecular Weight
- 93547.565 Da
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52